NasdaqCM - Delayed Quote USD

ChromaDex Corporation (CDXC)

3.4400

+0.0500

(+1.47%)

At close: 4:00 PM EDT

ChromaDex Announces Nationwide Launch of Tru Niagen® at The Vitamin Shoppe®

LOS ANGELES, April 25, 2024--ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) and healthy aging research, announces that its flagship consumer supplement, Tru Niagen®, is now available at The Vitamin Shoppe retail locations nationwide and online at www.vitaminshoppe.com. This retail expansion adds Tru Niagen to the shelves of 700 locations of The Vitamin Shoppe and Super Supplements, enhancing consumer access to the number one healthy-aging NAD+ sup

Business Wire yesterday

CDXC
+1.47%
ChromaDex to Report First Quarter 2024 Financial Results on Wednesday, May 8, 2024

LOS ANGELES, April 24, 2024--ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) and healthy aging research, announced that it will hold a conference call on Wednesday, May 8, 2024 at 4:30 p.m. ET to discuss its financial results for the first quarter, which ended March 31, 2024. The financial results will be reported in a press release after the close of regular stock market trading hours on the same day as the conference call.

Business Wire 2 days ago

CDXC
+1.47%
ChromaDex Announces Inaugural Major Grocery Debut of Tru Niagen® at Sprouts Farmers Market

LOS ANGELES, April 23, 2024--ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) and healthy aging research, announces that its flagship product, Tru Niagen®, the number one healthy-aging NAD+ supplement in the United States†, is now available at Sprouts Farmers Market, marking its inaugural major grocery debut. As one of the fastest-growing retailers in the United States, Sprouts Farmers Market now offers Tru Niagen to its health-conscious consumers i

Business Wire 3 days ago

CDXC
+1.47%
Should You Think About Buying ChromaDex Corporation (NASDAQ:CDXC) Now?

ChromaDex Corporation ( NASDAQ:CDXC ), might not be a large cap stock, but it led the NASDAQCM gainers with a...

Simply Wall St. 21 days ago

CDXC
+1.47%
Precision BioSciences (DTIL) Soars 13.4%: Is Further Upside Left in the Stock?

Precision BioSciences (DTIL) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Zacks 24 days ago

DTIL

CDXC
+1.47%
ChromaDex Announces Tru Niagen® is Now Third-Party Verified Through the Alkemist Assured™ Transparency Program

LOS ANGELES, March 26, 2024--ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) and healthy aging research, announces that its flagship Tru Niagen® product portfolio is now third-party verified through the Alkemist Assured™ testing transparency program by Alkemist Labs, a leading third-party testing laboratory known for its rigorous herbal and dietary supplement analysis. As the number one NAD+ supplement company in the US†, Tru Niagen features NIAGEN

Business Wire last month

CDXC
+1.47%
ChromaDex Full Year 2023 Earnings: EPS Beats Expectations

ChromaDex ( NASDAQ:CDXC ) Full Year 2023 Results Key Financial Results Revenue: US$83.6m (up 16% from FY 2022). Net...

Simply Wall St. last month

CDXC
+1.47%
ChromaDex Corp (CDXC) Reports Encouraging Fiscal Year 2023 Results with Positive Adjusted EBITDA

Net Sales Rise to $83.6 Million with a Notable Gross Margin Improvement

GuruFocus.com last month

CDXC
+1.47%
ChromaDex Corporation (NASDAQ:CDXC) Q4 2023 Earnings Call Transcript

ChromaDex Corporation (NASDAQ:CDXC) Q4 2023 Earnings Call Transcript March 6, 2024 ChromaDex Corporation beats earnings expectations. Reported EPS is $0.00152, expectations were $-0.03. ChromaDex Corporation isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Ladies and gentlemen, thank you for standing […]

Insider Monkey last month

CDXC
+1.47%
Q4 2023 Chromadex Corp Earnings Call

Q4 2023 Chromadex Corp Earnings Call

Thomson Reuters StreetEvents last month

CDXC
+1.47%
ChromaDex Corporation Reports Fourth Quarter and Fiscal Year 2023 Results

LOS ANGELES, March 06, 2024--ChromaDex Corp. (NASDAQ:CDXC) today announced fourth quarter and fiscal year 2023 financial results.

Business Wire last month

CDXC
+1.47%
Insiders own 26% of ChromaDex Corporation (NASDAQ:CDXC) shares but retail investors control 44% of the company

Key Insights ChromaDex's significant retail investors ownership suggests that the key decisions are influenced by...

Simply Wall St. last month

CDXC
+1.47%
ChromaDex to Report Fourth Quarter 2023 Financial Results on Wednesday, March 6, 2024

LOS ANGELES, February 21, 2024--ChromaDex Corp. (NASDAQ:CDXC) ("the Company"), a global bioscience company dedicated to healthy aging, announced that it will hold a conference call on Wednesday, March 6, 2024 at 4:30 p.m. ET to discuss its financial results for the fourth quarter, which ended December 31, 2023. The financial results will be reported in a press release after the close of regular stock market trading hours on the same day as the conference call.

Business Wire 2 months ago

CDXC
+1.47%
ChromaDex to Participate in Renmark’s Virtual Non-Deal Roadshow on Monday, February 12, 2024

LOS ANGELES, February 05, 2024--ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) and healthy aging research, announced today that it will be participating in Renmark Financial Communications Inc.’s live Virtual Non-Deal Roadshow Series to discuss its latest investor presentation on Monday, February 12, 2024, at 11:00 AM PST. ChromaDex welcomes stakeholders, investors, and other individual followers to register and attend this live event.

Business Wire 2 months ago

CDXC
+1.47%
ChromaDex to Present at the Lytham Partners 2024 Investor Select Conference

LOS ANGELES, January 26, 2024--ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) and healthy aging research, today announced that its Chief Executive Officer, Rob Fried, and Chief Financial Officer, Brianna Gerber, will be participating in the Lytham Partners 2024 Investor Select Conference.

Business Wire 2 months ago

CDXC
+1.47%
ChromaDex Corporation's (NASDAQ:CDXC) Shift From Loss To Profit

With the business potentially at an important milestone, we thought we'd take a closer look at ChromaDex Corporation's...

Simply Wall St. 3 months ago

CDXC
+1.47%
ChromaDex Supports the US Military with its Industry Leading NAD+ Supplement, Tru Niagen®

LOS ANGELES, December 20, 2023--ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) and healthy aging research, is proud to announce its inaugural initiative to support the US Military.

Business Wire 4 months ago

CDXC
+1.47%
Neurohacker Collective and ChromaDex Partner to Optimize Cellular Health with the Debut of Qualia NAD+

Neurohacker Collective, an acclaimed American science team that has been formulating advanced nutritional supplements since 2015, has just created an NAD+ supplement called Qualia NAD+ that tackles the challenge of boosting NAD+ levels in aging Americans.*

PR Newswire 4 months ago

CDXC
+1.47%
A Milestone Phase I Randomized, Double-Blind Clinical Trial Demonstrates High-Dose Niagen®, Patented Nicotinamide Riboside (NR), Supplementation Induces a Potent NAD+ Response and Is Associated With Mild Improvement in Parkinson's Disease (PD)

LOS ANGELES, November 30, 2023--ChromaDex Corp. (NASDAQ:CDXC), a global authority on Nicotinamide Adenine Dinucleotide (NAD+) and healthy aging research, shares results from a new breakthrough study analyzing the safety of high-dose nicotinamide riboside (NR) supplementation on individuals with Parkinson’s disease (PD). This study was part of the ChromaDex External Research Program (CERP™), which donated ChromaDex’s patented NR ingredient, Niagen®, the most efficient and high quality NAD+ precur

Business Wire 4 months ago

CDXC
+1.47%
An Intrinsic Calculation For ChromaDex Corporation (NASDAQ:CDXC) Suggests It's 44% Undervalued

Key Insights The projected fair value for ChromaDex is US$2.57 based on 2 Stage Free Cash Flow to Equity ChromaDex is...

Simply Wall St. 4 months ago

CDXC
+1.47%

Performance Overview

Return	CDXC	S&P 500
YTD	+140.56%	+6.92%
1-Year	+156.72%	+25.26%
3-Year	-57.79%	+22.00%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

ChromaDex Corporation (CDXC)

ChromaDex Announces Nationwide Launch of Tru Niagen® at The Vitamin Shoppe®

ChromaDex to Report First Quarter 2024 Financial Results on Wednesday, May 8, 2024

ChromaDex Announces Inaugural Major Grocery Debut of Tru Niagen® at Sprouts Farmers Market

Should You Think About Buying ChromaDex Corporation (NASDAQ:CDXC) Now?

Precision BioSciences (DTIL) Soars 13.4%: Is Further Upside Left in the Stock?

ChromaDex Announces Tru Niagen® is Now Third-Party Verified Through the Alkemist Assured™ Transparency Program

ChromaDex Full Year 2023 Earnings: EPS Beats Expectations

ChromaDex Corp (CDXC) Reports Encouraging Fiscal Year 2023 Results with Positive Adjusted EBITDA

ChromaDex Corporation (NASDAQ:CDXC) Q4 2023 Earnings Call Transcript

Q4 2023 Chromadex Corp Earnings Call

ChromaDex Corporation Reports Fourth Quarter and Fiscal Year 2023 Results

Insiders own 26% of ChromaDex Corporation (NASDAQ:CDXC) shares but retail investors control 44% of the company

ChromaDex to Report Fourth Quarter 2023 Financial Results on Wednesday, March 6, 2024

ChromaDex to Participate in Renmark’s Virtual Non-Deal Roadshow on Monday, February 12, 2024

ChromaDex to Present at the Lytham Partners 2024 Investor Select Conference

ChromaDex Corporation's (NASDAQ:CDXC) Shift From Loss To Profit

ChromaDex Supports the US Military with its Industry Leading NAD+ Supplement, Tru Niagen®

Neurohacker Collective and ChromaDex Partner to Optimize Cellular Health with the Debut of Qualia NAD+

A Milestone Phase I Randomized, Double-Blind Clinical Trial Demonstrates High-Dose Niagen®, Patented Nicotinamide Riboside (NR), Supplementation Induces a Potent NAD+ Response and Is Associated With Mild Improvement in Parkinson's Disease (PD)

An Intrinsic Calculation For ChromaDex Corporation (NASDAQ:CDXC) Suggests It's 44% Undervalued

Performance Overview